Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 8/20 | 0.53 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.45 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL1854716 | 0.98 | NR4A2 (0.54) | NR4A2MRGPRX4EGLN1MAOBPTGER1 | |
| Water SCHEMBL1854715 | 0.98 | NR4A2 (0.54) | NR4A2MRGPRX4EGLN1MAOBPTGER1 | |
| SCHEMBL1854941 | 0.89 | BRAF (0.46) | NR4A2MRGPRX4MAOB | |
| SCHEMBL3208707 | 0.87 | GPR52 (0.57) | MRGPRX4 | |
| SCHEMBL1851648 | 0.74 | BRAF (0.50) | NR4A2MRGPRX4KDM4C | |
| SCHEMBL3042303 | 0.72 | MRGPRX4 (0.74) | NR4A2MRGPRX4EGLN1MAOBFFAR1 | |
| SCHEMBL22480781 | 0.71 | MRGPRX4 (1.00) | NR4A2MRGPRX4MAOB | |
| SCHEMBL31568544 | 0.70 | MRGPRX4 (1.00) | NR4A2MRGPRX4 | |
| SCHEMBL22469939 | 0.70 | MRGPRX4 (1.00) | NR4A2MRGPRX4 | |
| SCHEMBL14014028 | 0.69 | NR4A2 (1.00) | NR4A2MRGPRX4MAOBFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323978-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010018874-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041891-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041891-A1 | AMIDE COMPOUND | GPR52, GPR132, NR5A2 | NR4A2 8/4885MRGPRX4 287/4885EGLN1 4055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.